ImmuneOnco’s IMM0306S Wins NMPA Approval – Subcutaneous CD47×CD20 Bispecific for Lupus Enters Clinic

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced clinical approval from China’s National Medical Products Administration (NMPA) for IMM0306S, the subcutaneous injection formulation of amulirafusp alfa. The company will initiate a clinical study assessing the CD47×CD20 bispecific molecule in systemic lupus erythematosus (SLE)—expanding the first‑in‑class asset from oncology into autoimmune disease.

Regulatory Milestone

Strategic Rationale – SLE Application

Formulation Differentiation

Strategic Implications

• First‑in‑Class Expansion: Amulirafusp alfa is the world’s first CD47×CD20 bispecific; the SLE indication validates platform versatility across oncology and autoimmunity, potentially creating dual‑market blockbuster value.
• Subcutaneous Advantage: The SC formulation addresses key barriers to chronic autoimmune therapy—infusion center dependency and treatment burden—supporting superior real‑world adherence vs. IV competitors.
• CD47 Safety Innovation: CD47 targeting historically carries anemia risk (CD47 expressed on RBCs); ImmuneOnco’s bispecific design with CD20 restriction may spare RBCs while maintaining efficacy—critical for SLE chronic dosing.
• Autoimmune Pipeline Validation: NMPA approval for SLE—following oncology INDs—demonstrates regulatory confidence in the CD47×CD20 mechanism for immune modulation, supporting additional autoimmune indications (rheumatoid arthritis, ITP, NMOSD).

Market Context

Forward‑Looking Statements
This brief contains forward‑looking statements regarding SLE Phase I enrollment, CD47 safety profile confirmation in autoimmune setting, and subcutaneous pharmacokinetic validation. Actual results may differ due to risks including CD47‑mediated anemia, competitive B‑cell depletion therapies, and SLE patient recruitment challenges.-Fineline Info & Tech